Accueil › Myélome multiple › Washington › Seattle
Essais cliniques pour Myélome multiple à Seattle, WA
22 études pour Myélome multiple recherchent des participants dans et autour de Seattle (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Recrutement en coursPhase 3
- Research Site, Seattle
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Recrutement en coursPhase 1/2
- University of Washington, Seattle
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Recrutement en coursPhase 2
- University of Washington, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recrutement en coursPhase 2
- Swedish Cancer Institute, Seattle
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Recrutement en coursPhase 3
- Fred Hutchinson Cancer Research Center, Seattle
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collection of Tissue Samples for Cancer Research
Recrutement en coursÉtude observationnelle
- Fred Hutchinson, Seattle
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 2
- Fred Hutchinson Cancer Center, Seattle
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Recrutement en coursPhase 3
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · à 17 mi
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recrutement en coursPhase 1/2
- Research Site, Seattle
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Recrutement en coursPhase 3
- Research Site, Seattle
- Research Site, Seattle
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Recrutement en coursPhase 1/2
- Fred Hutch Cancer Center, Seattle
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Recrutement en coursPhase 1
- VA Puget Sound Health Care System, Seattle
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Recrutement en coursPhase 3
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- et 1 autres
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Swedish Medical Center - Seattle /ID# 268052, Seattle
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- Swedish Cancer Institute, Seattle
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- Swedish Medical Center, Seattle
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Recrutement en cours
- University of Washington, Seattle
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Recrutement en cours
- University of Washington, Seattle
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Recrutement en coursÉtude observationnelle
- All4Cure, Seattle
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO27 études
- Rochester, MN24 études
- St. Louis, MO24 études
- Columbus, OH24 études
- Baldwin Park, CA23 études
- Chicago, IL22 études
Autres études à Seattle
- Cancer du poumon non à petites cellules53 études
- Cancer (tous types)49 études
- Cancer de la prostate42 études
- Leucémie aiguë myéloïde40 études
- Cancer du sein39 études
- Cancer métastatique39 études
- Cancer colorectal34 études
- Cancer du poumon33 études
- Cancer de l'ovaire30 études
- Syndromes myélodysplasiques21 études
- Leucémie aiguë lymphoblastique21 études
- Cancer de la vessie21 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.